Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SNRPD3 (ImmuneEditome ID:6634)

1. Gene summary of enriched editing regions for SNRPD3

Gene summary

Gene information	Gene symbol	SNRPD3
	Gene ID	6634
	GeneSynonyms	SMD3\|Sm-D3
	GeneCytomap	22q11.23
	GeneType	protein-coding
	GeneDescription	small nuclear ribonucleoprotein Sm D3\|small nuclear ribonucleoprotein D3 polypeptide 18kDa\|snRNP core protein D3
	GeneModificationdate	20230409
	UniprotID	P62318;H3BT13
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr22:24572464-24576575:+	ENST00000215829.6	ENSG00000100028.10	SNRPD3	UTR3	HAL1,AluY,MER5A1,AluJo,AluJb,AluJr,AluSx4,AluSq2	chr22:24572464-24576575:+.alignment

Top

2. Tumor-specific enriched editing regions for SNRPD3

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr22:24572464-24576575:+	BRCA	EER	5.3083e-52
ENSG00000100028.10,SNRPD3	BRCA	EAG	4.2768e-52
chr22:24572464-24576575:+	COAD	EER	1.1461e-30
ENSG00000100028.10,SNRPD3	COAD	EAG	1.0624e-30
chr22:24572464-24576575:+	HNSC	EER	2.0987e-19
ENSG00000100028.10,SNRPD3	HNSC	EAG	2.0987e-19
chr22:24572464-24576575:+	KICH	EER	1.7224e-08
ENSG00000100028.10,SNRPD3	KICH	EAG	1.7224e-08
chr22:24572464-24576575:+	KIRC	EER	1.0435e-03
ENSG00000100028.10,SNRPD3	KIRC	EAG	1.0422e-03
chr22:24572464-24576575:+	LUAD	EER	1.0130e-18
ENSG00000100028.10,SNRPD3	LUAD	EAG	9.7784e-19
chr22:24572464-24576575:+	LUSC	EER	4.1112e-04
ENSG00000100028.10,SNRPD3	LUSC	EAG	4.0407e-04
chr22:24572464-24576575:+	STAD	EER	2.4571e-02
ENSG00000100028.10,SNRPD3	STAD	EAG	2.4356e-02
chr22:24572464-24576575:+	THCA	EER	7.9143e-13
ENSG00000100028.10,SNRPD3	THCA	EAG	7.8330e-13
chr22:24572464-24576575:+	UCEC	EER	5.8561e-10
ENSG00000100028.10,SNRPD3	UCEC	EAG	5.0632e-10

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr22:24572464-24576575:+	ESCA	Cli	EER	4.4068e-02	2.0384e-02	-0.3178
ENSG00000100028.10,SNRPD3	ESCA	Cli	EAG	4.4248e-02	2.0445e-02	-0.3177
ENSG00000100028.10,SNRPD3	HNSC	Cli	EAG	4.4751e-02	2.0519e-02	0.1051
chr22:24572464-24576575:+	HNSC	Cli	EER	4.4751e-02	2.0519e-02	0.1051
ENSG00000100028.10,SNRPD3	KIRC	Path	EAG	1.1502e-03	3.9897e-03	0.1245
chr22:24572464-24576575:+	KIRC	Path	EER	1.1512e-03	3.9950e-03	0.1245
chr22:24572464-24576575:+	KIRP	Cli	EER	2.3494e-02	1.3788e-02	0.1739
ENSG00000100028.10,SNRPD3	KIRP	Cli	EAG	2.3494e-02	1.3788e-02	0.1739
chr22:24572464-24576575:+	READ	Path	EER	4.2069e-02	5.4781e-03	-0.2214
ENSG00000100028.10,SNRPD3	READ	Path	EAG	4.2069e-02	5.4781e-03	-0.2214
chr22:24572464-24576575:+	THCA	Path	EER	1.3122e-04	2.8252e-02	0.0978
ENSG00000100028.10,SNRPD3	THCA	Path	EAG	1.2645e-04	2.7671e-02	0.0982

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr22:24572464-24576575:+	PAAD	EER	1.3196e-02	1.3571e-02	4.3998e+03
ENSG00000100028.10,SNRPD3	PAAD	EAG	1.3196e-02	1.3571e-02	4.3998e+03

Top

3. Enriched editing regions and immune related genes for SNRPD3

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for SNRPD3

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for SNRPD3

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr22:24572464-24576575:+	BLCA	EER	Macrophages_M1	2.8931e-12	0.3374
ENSG00000100028.10,SNRPD3	BLCA	EAG	Macrophages_M1	3.5445e-12	0.3361
chr22:24572464-24576575:+	BRCA	EER	Dendritic_cells_activated	1.4069e-05	0.1315
ENSG00000100028.10,SNRPD3	BRCA	EAG	Dendritic_cells_activated	1.3214e-05	0.1320
chr22:24572464-24576575:+	CESC	EER	Macrophages_M0	1.5412e-09	-0.3376
ENSG00000100028.10,SNRPD3	CESC	EAG	Macrophages_M0	1.5412e-09	-0.3376
chr22:24572464-24576575:+	CHOL	EER	T_cells_CD4_naive	8.6977e-04	0.5375
ENSG00000100028.10,SNRPD3	CHOL	EAG	T_cells_CD4_naive	8.7129e-04	0.5374
chr22:24572464-24576575:+	COAD	EER	Neutrophils	3.2586e-02	0.1292
ENSG00000100028.10,SNRPD3	COAD	EAG	Plasma_cells	3.4555e-02	-0.1277
chr22:24572464-24576575:+	DLBC	EER	Mast_cells_resting	1.8341e-02	0.3392
ENSG00000100028.10,SNRPD3	DLBC	EAG	Mast_cells_resting	1.8341e-02	0.3392
chr22:24572464-24576575:+	ESCA	EER	Dendritic_cells_resting	4.1234e-03	-0.2249
ENSG00000100028.10,SNRPD3	ESCA	EAG	Dendritic_cells_resting	4.1175e-03	-0.2250
chr22:24572464-24576575:+	GBM	EER	Macrophages_M0	3.7040e-05	-0.3135
ENSG00000100028.10,SNRPD3	GBM	EAG	Macrophages_M0	3.6978e-05	-0.3135
chr22:24572464-24576575:+	HNSC	EER	Macrophages_M1	3.3397e-07	0.2260
ENSG00000100028.10,SNRPD3	HNSC	EAG	Macrophages_M1	3.3397e-07	0.2260
chr22:24572464-24576575:+	KICH	EER	Macrophages_M2	1.9131e-02	-0.2900
ENSG00000100028.10,SNRPD3	KICH	EAG	Macrophages_M2	1.9131e-02	-0.2900
chr22:24572464-24576575:+	KIRC	EER	T_cells_CD8	3.7790e-03	0.1473
ENSG00000100028.10,SNRPD3	KIRC	EAG	T_cells_CD8	3.7669e-03	0.1473
chr22:24572464-24576575:+	KIRP	EER	NK_cells_resting	1.9913e-04	0.2175
ENSG00000100028.10,SNRPD3	KIRP	EAG	NK_cells_resting	1.9913e-04	0.2175
chr22:24572464-24576575:+	LAML	EER	Mast_cells_resting	6.9804e-05	-0.3189
ENSG00000100028.10,SNRPD3	LAML	EAG	Mast_cells_resting	6.9804e-05	-0.3189
chr22:24572464-24576575:+	LGG	EER	Eosinophils	5.0733e-04	0.1507
ENSG00000100028.10,SNRPD3	LGG	EAG	Eosinophils	5.0733e-04	0.1507
chr22:24572464-24576575:+	LIHC	EER	Macrophages_M0	5.7235e-04	-0.1775
ENSG00000100028.10,SNRPD3	LIHC	EAG	Macrophages_M0	5.7235e-04	-0.1775
chr22:24572464-24576575:+	LUAD	EER	T_cells_CD4_memory_activated	1.1530e-07	0.2312
ENSG00000100028.10,SNRPD3	LUAD	EAG	T_cells_CD4_memory_activated	1.1896e-07	0.2310
chr22:24572464-24576575:+	LUSC	EER	T_cells_CD8	9.8407e-14	0.3252
ENSG00000100028.10,SNRPD3	LUSC	EAG	T_cells_CD8	1.0331e-13	0.3250
chr22:24572464-24576575:+	MESO	EER	Neutrophils	9.0365e-03	-0.2884
ENSG00000100028.10,SNRPD3	MESO	EAG	Neutrophils	9.0365e-03	-0.2884
chr22:24572464-24576575:+	OV	EER	Macrophages_M1	7.1774e-06	0.2593
ENSG00000100028.10,SNRPD3	OV	EAG	Macrophages_M1	6.9781e-06	0.2596
chr22:24572464-24576575:+	PAAD	EER	T_cells_CD8	3.2669e-03	-0.2193
ENSG00000100028.10,SNRPD3	PAAD	EAG	T_cells_CD8	3.2669e-03	-0.2193
chr22:24572464-24576575:+	PCPG	EER	T_cells_regulatory_(Tregs)	4.2962e-03	0.2102
ENSG00000100028.10,SNRPD3	PCPG	EAG	T_cells_regulatory_(Tregs)	4.2937e-03	0.2102
chr22:24572464-24576575:+	PRAD	EER	T_cells_CD4_memory_resting	1.6708e-06	0.2125
ENSG00000100028.10,SNRPD3	PRAD	EAG	T_cells_CD4_memory_resting	1.4239e-06	0.2139
chr22:24572464-24576575:+	SARC	EER	Macrophages_M1	5.7985e-04	0.2132
ENSG00000100028.10,SNRPD3	SARC	EAG	Macrophages_M1	5.7985e-04	0.2132
chr22:24572464-24576575:+	SKCM	EER	T_cells_CD8	6.8555e-11	0.2947
ENSG00000100028.10,SNRPD3	SKCM	EAG	T_cells_CD8	6.8555e-11	0.2947
chr22:24572464-24576575:+	STAD	EER	B_cells_naive	1.8575e-04	-0.1936
ENSG00000100028.10,SNRPD3	STAD	EAG	B_cells_naive	1.8172e-04	-0.1939
chr22:24572464-24576575:+	TGCT	EER	Macrophages_M2	6.8226e-12	-0.5139
ENSG00000100028.10,SNRPD3	TGCT	EAG	Macrophages_M2	6.7946e-12	-0.5140
chr22:24572464-24576575:+	THCA	EER	T_cells_regulatory_(Tregs)	2.1043e-06	0.2094
ENSG00000100028.10,SNRPD3	THCA	EAG	T_cells_regulatory_(Tregs)	2.0298e-06	0.2098
chr22:24572464-24576575:+	THYM	EER	Macrophages_M1	5.9335e-11	0.5567
ENSG00000100028.10,SNRPD3	THYM	EAG	Macrophages_M1	5.9335e-11	0.5567
chr22:24572464-24576575:+	UCEC	EER	Dendritic_cells_resting	5.6226e-03	-0.2073
ENSG00000100028.10,SNRPD3	UCEC	EAG	Dendritic_cells_resting	4.4967e-03	-0.2126
chr22:24572464-24576575:+	UCS	EER	Macrophages_M0	1.8786e-02	0.3131
ENSG00000100028.10,SNRPD3	UCS	EAG	Macrophages_M0	1.8786e-02	0.3131
chr22:24572464-24576575:+	UVM	EER	T_cells_CD4_memory_resting	2.5279e-03	-0.3332
ENSG00000100028.10,SNRPD3	UVM	EAG	T_cells_CD4_memory_resting	2.5279e-03	-0.3332

Top

6. Enriched editing regions and immune gene sets for SNRPD3

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr22:24572464-24576575:+	BLCA	EER	1.3430e-03	0.1586	2.0846e-03	0.1523	6.3692e-04	0.1688	3.1059e-04	0.1781
ENSG00000100028.10,SNRPD3	BLCA	EAG	1.4985e-03	0.1571	2.0947e-03	0.1523	7.2085e-04	0.1672	4.0776e-04	0.1746
chr22:24572464-24576575:+	LUAD	EER	1.7924e-07	0.2278	1.8295e-08	0.2450	3.2789e-06	0.2036	4.4468e-02	0.0887
ENSG00000100028.10,SNRPD3	LUAD	EAG	1.9053e-07	0.2273	1.8148e-08	0.2451	3.3953e-06	0.2032	4.6915e-02	0.0877
chr22:24572464-24576575:+	PAAD	EER	5.3577e-06	0.3336	3.8782e-05	0.3032	4.4612e-05	0.3010	5.7422e-03	0.2062
ENSG00000100028.10,SNRPD3	PAAD	EAG	5.3577e-06	0.3336	3.8782e-05	0.3032	4.4612e-05	0.3010	5.7422e-03	0.2062
chr22:24572464-24576575:+	THYM	EER	6.5778e-03	-0.2489	1.9054e-04	-0.3370	6.7487e-06	0.4011	5.6487e-11	0.5572
ENSG00000100028.10,SNRPD3	THYM	EAG	6.5778e-03	-0.2489	1.9054e-04	-0.3370	6.7487e-06	0.4011	5.6487e-11	0.5572

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr22:24572464-24576575:+	ACC	GSVA_HALLMARK_DNA_REPAIR	EER	4.2441e-03	-0.3204
ENSG00000100028.10,SNRPD3	ACC	GSVA_HALLMARK_DNA_REPAIR	EAG	4.2441e-03	-0.3204
chr22:24572464-24576575:+	BLCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.6027e-18	0.4148
ENSG00000100028.10,SNRPD3	BLCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.9800e-18	0.4127
chr22:24572464-24576575:+	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.3250e-26	0.3149
ENSG00000100028.10,SNRPD3	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.2337e-26	0.3119
ENSG00000100028.10,SNRPD3	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.1798e-22	0.5221
chr22:24572464-24576575:+	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1798e-22	0.5221
chr22:24572464-24576575:+	COAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.0457e-06	-0.2900
ENSG00000100028.10,SNRPD3	COAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	8.9950e-07	-0.2916
chr22:24572464-24576575:+	DLBC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.7581e-02	0.3413
ENSG00000100028.10,SNRPD3	DLBC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.7581e-02	0.3413
ENSG00000100028.10,SNRPD3	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.4362e-05	0.3160
chr22:24572464-24576575:+	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.4076e-05	0.3161
chr22:24572464-24576575:+	GBM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	7.2245e-07	-0.3724
ENSG00000100028.10,SNRPD3	GBM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	7.2637e-07	-0.3723
ENSG00000100028.10,SNRPD3	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.2927e-22	0.4188
chr22:24572464-24576575:+	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2927e-22	0.4188
ENSG00000100028.10,SNRPD3	KICH	GSVA_HALLMARK_APICAL_SURFACE	EAG	3.7379e-02	-0.2588
chr22:24572464-24576575:+	KICH	GSVA_HALLMARK_APICAL_SURFACE	EER	3.7379e-02	-0.2588
chr22:24572464-24576575:+	KIRC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	7.3955e-05	-0.2006
ENSG00000100028.10,SNRPD3	KIRC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	7.3892e-05	-0.2006
chr22:24572464-24576575:+	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.2934e-02	-0.1194
ENSG00000100028.10,SNRPD3	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.2934e-02	-0.1194
chr22:24572464-24576575:+	LAML	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	1.1651e-04	-0.3094
ENSG00000100028.10,SNRPD3	LAML	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.1651e-04	-0.3094
chr22:24572464-24576575:+	LGG	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.1600e-10	-0.2754
ENSG00000100028.10,SNRPD3	LGG	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.1600e-10	-0.2754
ENSG00000100028.10,SNRPD3	LIHC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	5.3220e-11	0.3312
chr22:24572464-24576575:+	LIHC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	5.3220e-11	0.3312
chr22:24572464-24576575:+	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.4496e-08	0.2384
ENSG00000100028.10,SNRPD3	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.7403e-08	0.2380
ENSG00000100028.10,SNRPD3	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.4610e-20	0.4000
chr22:24572464-24576575:+	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2691e-20	0.4006
chr22:24572464-24576575:+	MESO	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	5.2122e-03	-0.3076
ENSG00000100028.10,SNRPD3	MESO	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	5.2122e-03	-0.3076
ENSG00000100028.10,SNRPD3	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.1189e-21	0.5156
chr22:24572464-24576575:+	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.9876e-21	0.5158
ENSG00000100028.10,SNRPD3	PAAD	GSVA_HALLMARK_P53_PATHWAY	EAG	2.7814e-07	0.3737
chr22:24572464-24576575:+	PAAD	GSVA_HALLMARK_P53_PATHWAY	EER	2.7814e-07	0.3737
chr22:24572464-24576575:+	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0748e-03	0.2398
ENSG00000100028.10,SNRPD3	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0770e-03	0.2398
ENSG00000100028.10,SNRPD3	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.3875e-10	0.2695
chr22:24572464-24576575:+	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	8.0523e-10	0.2706
chr22:24572464-24576575:+	READ	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.8060e-05	0.4093
ENSG00000100028.10,SNRPD3	READ	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.8060e-05	0.4093
chr22:24572464-24576575:+	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	1.1801e-06	-0.2976
ENSG00000100028.10,SNRPD3	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.1801e-06	-0.2976
chr22:24572464-24576575:+	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.5692e-10	0.2821
ENSG00000100028.10,SNRPD3	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.5692e-10	0.2821
ENSG00000100028.10,SNRPD3	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.2799e-12	0.3588
chr22:24572464-24576575:+	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2185e-12	0.3591
ENSG00000100028.10,SNRPD3	TGCT	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	2.6207e-12	-0.5225
chr22:24572464-24576575:+	TGCT	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	2.6274e-12	-0.5225
ENSG00000100028.10,SNRPD3	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	8.7397e-11	0.2837
chr22:24572464-24576575:+	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	8.1790e-11	0.2841
chr22:24572464-24576575:+	THYM	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	6.1524e-13	0.6011
ENSG00000100028.10,SNRPD3	THYM	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	6.1524e-13	0.6011
chr22:24572464-24576575:+	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.9517e-08	0.3985
ENSG00000100028.10,SNRPD3	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.9905e-08	0.3984
ENSG00000100028.10,SNRPD3	UCS	GSVA_HALLMARK_MYOGENESIS	EAG	3.0895e-04	-0.4646
chr22:24572464-24576575:+	UCS	GSVA_HALLMARK_MYOGENESIS	EER	3.0895e-04	-0.4646
chr22:24572464-24576575:+	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	5.5150e-05	0.4350
ENSG00000100028.10,SNRPD3	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	5.5150e-05	0.4350

Top

7. Enriched editing regions and drugs for SNRPD3

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000100028.10,SNRPD3	ACC	BMS.509744	EAG	3.0991e-03	0.3308
chr22:24572464-24576575:+	ACC	BMS.509744	EER	3.0991e-03	0.3308
chr22:24572464-24576575:+	BLCA	Axitinib	EER	1.3653e-15	0.3825
ENSG00000100028.10,SNRPD3	BLCA	Axitinib	EAG	3.2007e-15	0.3778
chr22:24572464-24576575:+	BRCA	CHIR.99021	EER	3.6046e-12	0.2092
ENSG00000100028.10,SNRPD3	BRCA	CHIR.99021	EAG	4.4285e-12	0.2084
chr22:24572464-24576575:+	CESC	ABT.888	EER	7.0515e-09	-0.3244
ENSG00000100028.10,SNRPD3	CESC	ABT.888	EAG	7.0515e-09	-0.3244
ENSG00000100028.10,SNRPD3	CHOL	FH535	EAG	7.8910e-03	-0.4417
chr22:24572464-24576575:+	CHOL	FH535	EER	7.8978e-03	-0.4417
ENSG00000100028.10,SNRPD3	COAD	GW843682X	EAG	1.5330e-08	0.3335
chr22:24572464-24576575:+	COAD	GW843682X	EER	3.1812e-08	0.3264
chr22:24572464-24576575:+	DLBC	GW.441756	EER	9.6005e-03	0.3702
ENSG00000100028.10,SNRPD3	DLBC	GW.441756	EAG	9.6005e-03	0.3702
ENSG00000100028.10,SNRPD3	ESCA	ABT.263	EAG	1.3524e-02	0.1949
chr22:24572464-24576575:+	ESCA	ABT.263	EER	1.3305e-02	0.1954
ENSG00000100028.10,SNRPD3	GBM	BIBW2992	EAG	2.9549e-08	-0.4128
chr22:24572464-24576575:+	GBM	BIBW2992	EER	2.9051e-08	-0.4130
ENSG00000100028.10,SNRPD3	HNSC	FH535	EAG	2.5873e-10	0.2781
chr22:24572464-24576575:+	HNSC	FH535	EER	2.5873e-10	0.2781
ENSG00000100028.10,SNRPD3	KICH	ABT.263	EAG	3.0159e-05	0.4930
chr22:24572464-24576575:+	KICH	ABT.263	EER	3.0159e-05	0.4930
chr22:24572464-24576575:+	KIRC	Bicalutamide	EER	3.0459e-06	0.2353
ENSG00000100028.10,SNRPD3	KIRC	Bicalutamide	EAG	3.0406e-06	0.2353
chr22:24572464-24576575:+	KIRP	GSK.650394	EER	9.3018e-06	0.2579
ENSG00000100028.10,SNRPD3	KIRP	GSK.650394	EAG	9.3018e-06	0.2579
chr22:24572464-24576575:+	LAML	GW.441756	EER	4.7826e-06	0.3636
ENSG00000100028.10,SNRPD3	LAML	GW.441756	EAG	4.7826e-06	0.3636
chr22:24572464-24576575:+	LGG	Gemcitabine	EER	1.1603e-09	0.2606
ENSG00000100028.10,SNRPD3	LGG	Gemcitabine	EAG	1.1603e-09	0.2606
ENSG00000100028.10,SNRPD3	LIHC	BMS.754807	EAG	5.1940e-17	0.4166
chr22:24572464-24576575:+	LIHC	BMS.754807	EER	5.1940e-17	0.4166
chr22:24572464-24576575:+	LUAD	CMK	EER	2.8507e-08	-0.2418
ENSG00000100028.10,SNRPD3	LUAD	CMK	EAG	2.6576e-08	-0.2423
chr22:24572464-24576575:+	LUSC	AP.24534	EER	3.6833e-09	0.2604
ENSG00000100028.10,SNRPD3	LUSC	AP.24534	EAG	3.5030e-09	0.2607
ENSG00000100028.10,SNRPD3	MESO	Gefitinib	EAG	4.8759e-03	-0.3099
chr22:24572464-24576575:+	MESO	Gefitinib	EER	4.8759e-03	-0.3099
ENSG00000100028.10,SNRPD3	OV	Axitinib	EAG	2.6731e-11	0.3771
chr22:24572464-24576575:+	OV	Axitinib	EER	2.6080e-11	0.3773
chr22:24572464-24576575:+	PAAD	BIBW2992	EER	2.9706e-06	-0.3420
ENSG00000100028.10,SNRPD3	PAAD	BIBW2992	EAG	2.9706e-06	-0.3420
chr22:24572464-24576575:+	PCPG	Midostaurin	EER	1.3270e-04	0.2788
ENSG00000100028.10,SNRPD3	PCPG	Midostaurin	EAG	1.3281e-04	0.2788
ENSG00000100028.10,SNRPD3	PRAD	JNK.Inhibitor.VIII	EAG	6.6750e-10	-0.2718
chr22:24572464-24576575:+	PRAD	JNK.Inhibitor.VIII	EER	7.9948e-10	-0.2706
chr22:24572464-24576575:+	READ	Imatinib	EER	1.6100e-02	0.2464
ENSG00000100028.10,SNRPD3	READ	Imatinib	EAG	1.6100e-02	0.2464
chr22:24572464-24576575:+	SARC	Axitinib	EER	3.0311e-06	0.2865
ENSG00000100028.10,SNRPD3	SARC	Axitinib	EAG	3.0311e-06	0.2865
chr22:24572464-24576575:+	SKCM	AG.014699	EER	8.0461e-12	0.3085
ENSG00000100028.10,SNRPD3	SKCM	AG.014699	EAG	8.0461e-12	0.3085
ENSG00000100028.10,SNRPD3	STAD	ABT.263	EAG	3.7482e-06	0.2394
chr22:24572464-24576575:+	STAD	ABT.263	EER	3.4376e-06	0.2403
ENSG00000100028.10,SNRPD3	TGCT	Docetaxel	EAG	8.0462e-09	0.4414
chr22:24572464-24576575:+	TGCT	Docetaxel	EER	8.0679e-09	0.4414
ENSG00000100028.10,SNRPD3	THCA	CI.1040	EAG	3.6716e-15	-0.3407
chr22:24572464-24576575:+	THCA	CI.1040	EER	3.4774e-15	-0.3409
chr22:24572464-24576575:+	THYM	Bleomycin	EER	9.5186e-14	0.6175
ENSG00000100028.10,SNRPD3	THYM	Bleomycin	EAG	9.5186e-14	0.6175
chr22:24572464-24576575:+	UCEC	ABT.888	EER	3.1189e-06	-0.3423
ENSG00000100028.10,SNRPD3	UCEC	ABT.888	EAG	2.3164e-06	-0.3465
chr22:24572464-24576575:+	UCS	Gefitinib	EER	4.6899e-04	-0.4521
ENSG00000100028.10,SNRPD3	UCS	Gefitinib	EAG	4.6899e-04	-0.4521
chr22:24572464-24576575:+	UVM	CGP.60474	EER	1.2512e-06	-0.5114
ENSG00000100028.10,SNRPD3	UVM	CGP.60474	EAG	1.2512e-06	-0.5114

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType